Immutep is concentrating future eftilagimod alfa development on head and neck cancer with negative PD-L1 expression and neoadjuvant soft tissue sarcoma. The strategy matters to investors because it ties the next clinical path to Manufacturing analysis, regulatory discussions, trial design, partnering and available resources.

Key Highlights

  • Manufacturing analysis found structural differences between smaller-scale and larger-scale efti production.
  • Immutep has contracted a new manufacturing run using the scale associated with earlier successful clinical studies.
  • Dr. Reddy’s Laboratories supports the proposed development approach, while discussions with other parties continue.

The company is pursuing a new manufacturing run after its analysis found structural differences between product batches used in different clinical studies.

Efti Focus Narrows to HNSCC and STS

The FDA has granted Fast Track Designation for HNSCC and Orphan Drug Designation for soft tissue sarcoma.

Manufacturing Review Sets Next Development Conditions

The root cause analysis followed the early discontinuation of a clinical study and identified structural differences between efti made at smaller and larger production scales, including a subtle difference in N-glycan structure. Immutep (NASDAQ: IMMP) said the available evidence does not point to clinical or trial-execution factors as the explanation for the unexpected outcome. A new manufacturing run at the earlier scale has been contracted, and the company plans to provide another update when the analysis is complete. Dr. Reddy’s Laboratories has been consulted and supports the approach, while Immutep is holding preliminary discussions with other parties about the proposed pathway.